Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Biocartis Group NV    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
4.55(c) 4.53(c) 4.565(c) 4.615(c) 4.685 Last
44 762 61 889 74 802 78 749 41 236 Volume
+1.00% -0.44% +0.77% +1.10% +1.52% Change
More quotes
Financials
Sales 2020 48,5 M 54,9 M 54,9 M
Net income 2020 -59,2 M -67,0 M -67,0 M
Net Debt 2020 54,0 M 61,2 M 61,2 M
P/E ratio 2020 -4,33x
Yield 2020 -
Sales 2021 68,1 M 77,1 M 77,1 M
Net income 2021 -48,5 M -54,9 M -54,9 M
Net Debt 2021 113 M 128 M 128 M
P/E ratio 2021 -5,24x
Yield 2021 -
Capitalization 260 M 294 M 295 M
EV / Sales 2020 6,48x
EV / Sales 2021 5,48x
Nbr of Employees 462
Free-Float 81,4%
More Financials
Company
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes. Net sales by source of income... 
More about the company
Surperformance© ratings of Biocartis Group NV
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOCARTIS GROUP NV
06/26PRESS RELEASE BIOCARTIS GROUP NV : US Multicenter Study Shows Idylla™ Allo..
AQ
05/08PRESS RELEASE BIOCARTIS GROUP NV : Results of the Shareholders' Meetings held on..
AQ
04/30PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Creates New Share Option Plan
AQ
04/23PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Q1 2020 Business Update
AQ
04/23PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Development of Idylla&tr..
AQ
04/23BIOCARTIS GROUP NV : 1st quarter results
CO
04/21BIOCARTIS GROUP NV : Important Notice Regarding the Annual and Extraordinary Sha..
AQ
04/20PRESS RELEASE BIOCARTIS GROUP NV : Important Notice Regarding the Annual and Ext..
AQ
04/07PRESS RELEASE BIOCARTIS GROUP NV : Invitation to the Annual and Extraordinary Sh..
AQ
04/07BIOCARTIS GROUP NV : Mixed general shareholder meeting
CO
04/02PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Publication of 2019 Annua..
AQ
03/26BIOCARTIS : Announces Co-Commercialization of the SeptiCyte® RAPID Test on Idyll..
AQ
03/05BIOCARTIS : Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aime..
AQ
03/05PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2019 results and 2020 out..
AQ
03/05PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Creates New Share Option Plan & Can..
AQ
More news
News in other languages on BIOCARTIS GROUP NV
06/30AVIS D'ANALYSTES DU JOUR : Axa, Barry Callebaut, Campari, Seb, Michelin, Pernod ..
06/30Ça aurait pu être pire
06/26PRESS RELEASE BIOCARTIS GROUP NV : US Multicenter Study Shows Idylla™ Allo..
05/08PRESS RELEASE BIOCARTIS GROUP NV : Results of the Shareholders' Meetings held on..
04/30PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Creates New Share Option Plan
More news
Chart BIOCARTIS GROUP NV
Duration : Period :
Biocartis Group NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCARTIS GROUP NV
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,70 €
Last Close Price 4,62 €
Spread / Highest target 193%
Spread / Average Target 132%
Spread / Lowest Target 43,0%
EPS Revisions
Managers
NameTitle
Herman Verrelst Chief Executive Officer & Executive Director
Christian Reinaudo Independent Chairman
Piet Houwen Chief Operating Officer
Jean-Marc Roelandt Chief Financial Officer
Benoit Devogelaere Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
BIOCARTIS GROUP NV-19.32%294
ABBOTT LABORATORIES7.11%164 573
MASIMO CORPORATION46.23%12 508
ASAHI INTECC CO., LTD.-6.25%7 320
NOVOCURE LIMITED-28.35%6 065
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.95.28%5 682